RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
Sponsor: M.D. Anderson Cancer Center
This PHASE1/PHASE2 trial investigates Acute Lymphocytic Leukemia and Leukemia and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jul 2018 — Mar 2019 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .